FCMT
TXMD icon

Founders Capital Management (Texas)’s TherapeuticsMD TXMD Stock Holding History

Founders Capital Management (Texas)’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-200
Closed -$12K – 330
2021
Q2 		$12K Buy
+200
New +$12.1K 0.01% 253

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Founders Capital Management (Texas)'s TXMD Position: Q3 2021 in Review

Founders Capital Management (Texas) sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 200 shares — an estimated $12K sold.

Founders Capital Management (Texas) first reported a position in TXMD in Q2 2021 and held it in 1 quarter. The position peaked at $12K in Q2 2021. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

  • Founders Capital Management (Texas) reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
  • Founders Capital Management (Texas) sold 200 TherapeuticsMD shares in Q3 2021, an estimated $12K.
  • Founders Capital Management (Texas) first reported a position in TherapeuticsMD in Q2 2021 and held it in 1 quarter.
  • Founders Capital Management (Texas)'s TherapeuticsMD position peaked at $12K in Q2 2021.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on Founders Capital Management (Texas)'s 13F filing for Q3 2021, filed 12 Oct 2021.